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Efforts to improve antibiotic use in hospitals are consistently hampered by the complexity of 
medical decision making surrounding antibiotic administration. In addition to the myriad 
factors that influence a decision to start ntibiotics in the first place, there are a variety of 
issues that might change frequently during a course of therapy that can impact the decision 
to continue, change, or stop antibiotics.
There is certainly a great need to improve the way clinicians make decisions to start 
antibiotics. Better education and availability of information at the point of care on optimal 
diagnosis and treatment of infectious syndromes and on antibiotic spectra and dosing will 
lead to more effective decisions on the initiation of antibiotics. Interventions at the time of 
antibiotic prescribing using decision support or prior approval programs have proven highly 
effective in improving the way we start antibiotics.1,2
Just as important as the decision to start antibiotics is the decision to continue them. 
Antibiotics are often started in settings where their utility is unclear. Hence, the need for 
continued antibiotic therapy needs to be regularly reassessed in light of ever-changing 
clinical information. At least it should. Too often, antibiotics are started and simply 
continued without critical reappraisal.
One excellent strategy for improving reexamination of antibiotic treatments is to define 
specific moments when changes in therapy are especially likely to be important. This is a 
lesson learned from the World Health Organization hand hygiene campaign. Rather than 
simply telling people to clean their hands, the Clean Hands Campaign developed the My 5 
Moments for Hand Hygiene approach, which lays out specific times during patient care 
when hand hygiene is especially critical.3 Essential to applying this approach to antibiotics 
is, of course, the definition of these key moments in antibiotic therapy.
Given that microbiologic results are perhaps the single most important determinant of 
optimal antibiotics, a critical reassessment of therapy after 2 or 3 days, when culture results 
are likely to be available, seems warranted whenever antibiotics are used in hospitals. This 
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has led to the concept of an “antibiotic time-out,” much like the procedure time-outs that 
have become standard practice before surgery. The idea is to pause and review a patient’s 
antibiotics after 2 or 3 days in light of not just the culture results but also the clinical 
response and other information that was not available when the antibiotics were started.
In addition to an antibiotic time-out after 2 or 3 days of treatment, there are other key 
moments when an antibiotic time-out is warranted, as demonstrated in the article by 
Shaughnessy et al4 in this issue of Infection Control and Healthcare Epidemiology. In this 
excellent study, investigators from the Minneapolis Veterans Affairs Medical Center 
examined antibiotic therapy in patients with a new diagnosis of Clostridium difficile 
infection (CDI). Treatment guidelines for C. difficile emphasize the importance of 
evaluating and stopping all unnecessary antibiotics as a key part of treatment.5 Indeed, as the 
authors of this study point out, non-CDI antibiotics not only lower cure rates for CDI but 
also can increase the risk of disease recurrence.6,7 Shaughnessy and colleagues reviewed 
charts of patients who had a new diagnosis of CDI to see how often these patients were 
receiving unnecessary antibiotics. Each chart was reviewed by 2 infectious disease 
specialists, and necessity of therapy was based on whether the patient had an infection that 
required an antibiotic. In cases where an antibiotic was deemed necessary, the duration of 
therapy was also reviewed. The primary outcome was the total number of unnecessary 
antibiotic days.
Their findings, while discouraging, do point out a critical opportunity for improvement. 
More than half (57%) of all patients with a new diagnosis of CDI received a non-CDI 
antibiotic at some point in the month following the CDI diagnosis. Of these 141 patients, 
only 23% (33) received fully optimal non-CDI antibiotic treatment, meaning they received 
no unnecessary doses of antibiotics. The vast majority of patients, 76%, received at least 1 
unnecessary dose of an antibiotic. But most importantly, 36 of the 141 patients—or 26%—
received only unnecessary antibiotics following a new diagnosis of CDI. Of the 2,147 
antimicrobial days that occurred during a CDI and the 30 days following CDI treatment, 964 
(45%) included at least 1 unnecessary antimicrobial, and 763 (36%) included only 
unnecessary antimicrobials. The authors examined several potential predictors of 
unnecessary antibiotic therapy but did not find any particular patient or clinician factors that 
predicted unnecessary use. One encouraging finding was that patients who were immune 
suppressed were less likely to receive unnecessary antibiotics.
Even more important, the authors examined the diagnoses for which unnecessary antibiotics 
were given. These results were particularly eye-opening. More often than not, antibiotics for 
empiric therapy for fever and leukocytosis, urinary tract infection, and pneumonia were 
unwarranted. Indeed, unnecessary antibiotic days accounted for 81% of all antibiotic days 
given for urinary tract infection. Taken together, these 3 indications accounted for 60% of all 
unnecessary antibiotic days following a new diagnosis of CDI, with urinary tract infection 
and pneumonia combined accounting for nearly 50%. This finding fits well with the results 
of other studies showing significant inappropriate antibiotic treatment for these 2 commonly 
diagnosed infections.8,9
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It is impossible to say exactly how much of an impact reducing these unnecessary antibiotic 
days would have on CDI, although there is no doubt that it would have some impact. Several 
studies have shown that reducing antibiotic days will avert CDI.10,11 It is interesting to note 
that in this study CDI recurred in 47% of patients who received only unnecessary antibiotics, 
nearly double the usually reported recurrence rate for CDI. This certainly suggests an 
important opportunity for prevention.
We should applaud Shaughnessy and colleagues for performing a study that provides 
concrete data for action. The authors have shown us another critical moment for an antibiotic 
time-out—anytime a new diagnosis of CDI is made. A major benefit to promoting a time-out 
with a new CDI diagnosis is that the antibiotic reassessment has immediate and direct 
benefits to the individual patient: higher cure rates and lower risk of recurrent disease. This 
should make the time-out that much more acceptable—and even desirable—to providers. 
Moreover, the authors have shown us that if we can prompt critical reappraisal of antibiotics 
being given for just 2 infections—urinary tract infections and pneumonia—we could 
potentially reduce unnecessary antibiotic use in hospitals by half. Highlighting key moments 
for antibiotic time-outs is one way we can make antibiotic stewardship a core part of every 
clinician’s practice. Shaughnessy and colleagues have shown us the opportunity; our next 
challenge will be to seize it.
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